



## ASX Announcement

### **Medlab (ASX:MDC) awaiting final approvals from UK Government for importation licence for NanoCBD™**

SYDNEY, April 12, 2022 - Medlab Clinical Ltd (ASX:MDC) is pleased to announce it is ready to export NanoCBD™ to the United Kingdom.

- NanoCBD™ is ready for UK markets
- Awaiting final import license from UK Government – all other licenses granted
- UK prescribers already seeking approval for use in anticipation of NanoCBD™ arrival
- NanoCBD™ UK costs as a private script (patient payable) are £130 per unit.

Presently NanoCBD™ has been manufactured and quality assured for export to the UK for compassionate use. Medlab is currently awaiting final importation approval from the UK government, with all other necessary licenses granted.

Dr Sean Hall, CEO of Medlab said “NanoCBD™ is our first cannabinoid to enter the UK under an approved compassionate program. Our partners WEP Clinical in the UK have all licenses in place to distribute and supply under the UK Named Patient Program (NPP) which in a number of ways is similar to the Australian Special Access Scheme (SAS).”

Mr. Tony Potter, Head of the Pharmaceuticals at Medlab stated “There are a number of prescriber approvals in the UK awaiting the product, which is subject to the final importation approval by the UK government. Pricing for NanoCBD™ is expected to be around GBP130, and training on NanoCBD™ commenced two months ago.”

NanoCBD™ is the first of two cannabinoid programs to launch in the UK, and will be closely followed by NanaBis™, renamed as NanaDol due to naming conventions associated with exporting non-approved pharmaceutical agents from Australia. The NanaBis™/NanaDol program is in manufacture with heightened chemistry to improve its non-refrigeration shelf life.



### **About NanoCBD™**

NanoCBD™ is Medlab's second cannabinoid development sharing a number of similar elements from our late stage NanaBis™ program.

NanoCBD™ is currently available under the Australian Special Access Scheme as a CBD drug substance enhanced by Medlab's patented NanoCelle® delivery system.

**- ENDS -**

### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

### **About Medlab Clinical:**

Medlab Clinical Ltd (ASX:MDC) is pioneering the development and commercialisation of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain.

NanoCelle®, the patented delivery system is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit [www.medlab.co](http://www.medlab.co)

**Medlab** – *better medicines, better patient care*

### **Contact**

Medlab Clinical Limited  
Sean Hall, CEO  
[Sean\\_hall@medlab.co](mailto:Sean_hall@medlab.co)